Investigation Alert: Long-Term Investors in Nektar Therapeutics (NASDAQ: NKTR) should contact the Shareholders Foundation

An investigation was announced for current long-term investors in shares of Nektar Therapeutics (NASDAQ: NKTR) concerning potential breaches of fiduciary duties by certain directors and officers of Nektar Therapeutics.

Investors who are current long term investors in Nektar Therapeutics (NASDAQ: NKTR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: NKTR stocks follows a lawsuit filed against Nektar Therapeutics over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: NKTR stocks, concerns whether certain Nektar Therapeutics directors are liable in connection with the allegations made in that lawsuit.

San Francisco, CA based Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.

In March 2024, Nektar Therapeutics initiated its Phase 2b REZOLVE-AA trial, which was purportedly designed to evaluate rezpegaldesleukin in ninety-four patients with severe-to-very severe alopecia areata who had not previously been treated with a Janus kinase inhibitor or another biologic. The trial's enrollment criteria purportedly included a diagnosis of severe-to-very severe alopecia areata as measured using the Severity of Alopecia Tool score at both screening and randomization, as well as exclusion of patients who had experienced an unstable course of alopecia areata over the prior six months, had inadequate washout of prior alopecia areata treatments within eight weeks, or who had diffuse alopecia or other forms of alopecia.

In February 2025, Nektar Therapeutics announced that it had completed its target enrollment in the REZOLVE-AA trial. At all relevant times, Defendants maintained that enrollment in the trial had followed applicable instructions and protocol standards, while also touting the Company's purported drug development expertise and use of this expertise to advance its product candidates through clinical development.

Nektar Therapeutics (NASDAQ: NKTR) reported that its annual Total Revenue declined from $98.42 million in 2024 to $55.23 million in 2025, and that its Net Loss increased from $118.96 million in 2024 to $164.07 million in 2025.

The truth began to emerge on December 16, 2025, when Nektar issued a press release during pre-market hours "announc[ing] topline results from the 36-week induction treatment period of the Phase 2b REZOLVE-AA trial of investigational rezpegaldesleukin[.]" The press release disclosed that the trial failed to reach statistical significance, which Nektar attributed to the inclusion of four patients who should not have been eligible to participate.

Shares of Nektar Therapeutics (NASDAQ: NKTR) declined from $66.92 per share on October 31, 2025, to as low as $34.34 per share on Janaury 15, 2026.

According to that complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges that, the defendants made false and/or misleading statements and/or failed to disclose that enrollment in the rezpegaldesleukin REZOLVE-AA trial had not followed applicable instructions and protocol standards, that this was likely to have a significant negative impact on the REZOLVE-AA trial's results, and that accordingly, the REZOLVE-AA trial's overall integrity and prospects were overstated.

Those who purchased shares of Nektar Therapeutics (NASDAQ: NKTR) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.